HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 78.1%

Neg 0% Neu 0% Pos 78.1%

HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $35 to $40.